Certolizumab pegol, a monthly subcutaneously administered Fc-free anti-TNFalpha, improves health-related quality of life in patients with moderate to severe Crohn's disease.
Journal Information
Full Title: Int J Colorectal Dis
Abbreviation: Int J Colorectal Dis
Country: Unknown
Publisher: Unknown
Language: N/A
Publication Details
Subject Category: Gastroenterology
Available in Europe PMC: Yes
Available in PMC: Yes
PDF Available: No
Related Papers from Same Journal
Transparency Score
Transparency Indicators
Click on green indicators to view evidence textCore Indicators
"Conflicts of interest statement Stefan Schreiber, Richard Fedorak, and Brian Feagan have served as consultants for UCB. Dorothy Keininger and Liz O’Neil are employees of UCB. Paul Rutgeerts has served as consultant for UCB and received speaker fees and research support."
"This study was supported by a research grant from UCB, Slough, UK."
Additional Indicators
Assessment Info
Tool: rtransparent
OST Version: N/A
Last Updated: Aug 05, 2025